Article Sidebar
Main Article Content
The Knockdown of USP34 Inhibits the Progression of Hepatocellular Carcinoma by Accelerating c-Myc Degradation
Main Article Content
Abstract
Background/Aims: The function and mechanism of ubiquitin-specific protease 34 (USP34) in hepatocellular carcinoma (HCC) were explored to provide new molecular targets for treating HCC.
Materials and Methods: In the present study, bioinformatics techniques, quantitative real-time polymerase chain reaction, and western blot were used to detect the level of USP34 in HCC tissues and cell lines. Small interfering RNA of USP34 was transfected into HCC cells, and then Cell Counting Kit-8 (CCK-8) assay, wound healing assay, and transwell assay were performed to verify the proliferation, migration and invasion of HCC cells. Enzyme-linked immunosorbent assay was utilized to assess the glycolysis level in HCC cells. Co-immunoprecipitation was used to evaluate the ubiquitination level of cellular Myc (c-Myc).
Results: The expression of USP34 was upregulated in HCC patients and strongly associated with worse outcomes. Meanwhile, interference with USP34 suppressed the proliferation, migration, and invasion of HCC cells. In addition, silencing of USP34 reduced the glucose uptake, lactate production and ATP content in HCC cells, as well as downregulated the expression levels of glycolysis-related proteins (hexokinase 2, glucose transporter 1, pyruvate kinase M2, and lactate dehydrogenase A). Furthermore, the knockdown of USP34 enhanced the ubiquitination level of c-Myc and increased the degradation of c-Myc. Overexpression of c-Myc reverted the inhibitory effects of si-USP34 on the malignant biological behavior in HCC cells.
Conclusion: The USP34 regulates aerobic glycolysis and inhibits the progression of HCC by accelerating c-Myc ubiquitinated degradation.
Cite this article as: Liu H, Wei X, Nie Y, Liu J, Fan M. The knockdown of USP34 inhibits the progression of hepatocellular carcinoma by accelerating c-myc degradation. Turk J Gastroenterol. Published online April 21, 2024. doi 10.5152/tjg.2025.24335
Article Details
References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. [CrossRef]
2. Crocetti L, Bargellini I, Cioni R. Loco-regional treatment of HCC: current status. Clin Radiol. 2017;72(8):626-635. [CrossRef]
3. Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42(3):629-652. [CrossRef]
4. Ji F, Zhang ZH, Zhang Y, et al. Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection. BMC Cancer. 2018;18(1):460. [CrossRef]
5. Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23-36. [CrossRef]
6. Wang S, Zhou L, Ji N, et al. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression. Drug Resist Updat. 2023;69:100976. [CrossRef]
7. Yu Q, Dai W, Ji J, et al. Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway. J Cell Mol Med. 2022;26(10):3031-3045. [CrossRef]
8. Xia P, Zhang H, Lu H, et al. METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun (Lond). 2023;43(3):338-364. [CrossRef]
9. Martins Pinto M, Paumard P, Bouchez C, et al. The Warburg effect and mitochondrial oxidative phosphorylation: friends or foes? Biochim Biophys Acta Bioenerg. 2023;1864(1):148931. [CrossRef]
10. Xie Y, Wang M, Xia M, Guo Y, Zu X, Zhong J. Ubiquitination regulation of aerobic glycolysis in cancer. Life Sci. 2022;292:120322. [CrossRef]
11. Feng J, Li J, Wu L, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):126. [CrossRef]
12. Chen R, Zhang H, Li L, et al. Roles of ubiquitin-specific proteases in inflammatory diseases. Front Immunol. 2024;15:1258740. [CrossRef]
13. Dong X, Liu Z, Zhang E, et al. USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma. Cell Signal. 2021;85:110068. [CrossRef]
14. Kim SC, Kim J, Kim DW, et al. Methylation-sensitive high-resolution melting analysis of the USP44 promoter can detect early-stage hepatocellular carcinoma in blood samples. BMB Rep. 2022;55(11):553-558. [CrossRef]
15. Tang J, Long G, Xiao L, Zhou L. USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through β-catenin stabilization. Cell Death Dis. 2023;14(6):360. [CrossRef]
16. Gu Z, Lin C, Hu J, Xia J, Wei S, Gao D. USP34 regulated human pancreatic cancer cell survival via AKT and PKC pathways. Biol Pharm Bull. 2019;42(4):573-579. [CrossRef]
17. Farrell AS, Sears RC. MYC degradation. Cold Spring Harb Perspect Med. 2014;4(3):a014365. [CrossRef]
18. Gao H, Yin J, Ji C, et al. Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application. J Exp Clin Cancer Res. 2023;42(1):225. [CrossRef]
19. Yang H, Zhang X, Lao M, et al. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Cell Death Differ. 2023;30(2):560-575. [CrossRef]
20. Tang J, Long G, Hu K, et al. Targeting USP8 inhibits O-GlcNAcylation of SLC7A11 to promote ferroptosis of hepatocellular carcinoma via stabilization of OGT. Adv Sci (Weinh). 2023;10(33):e2302953. [CrossRef]
21. Zhao J, Guo J, Wang Y, et al. Research progress of DUB enzyme in hepatocellular carcinoma. Front Oncol. 2022;12:920287. [CrossRef]
22. Dai WL, Yuan SX, Cao JP. The deubiquitinase USP34 stabilizes SOX2 and induces cell survival and drug resistance in laryngeal squamous cell carcinoma. Kaohsiung J Med Sci. 2020;36(12):983-989. [CrossRef]
23. Guo YC, Wang MY, Zhang SW, et al. Ubiquitin-specific protease USP34 controls osteogenic differentiation and bone formation by regulating BMP2 signaling. EMBO J. 2018;37(20). [CrossRef]
24. Lin C, Xia J, Gu Z, Meng Y, Gao D, Wei S. Downregulation of USP34 inhibits the growth and migration of pancreatic cancer cells via inhibiting the PRR11. Onco Targets Ther. 2020;13:1471-1480. [CrossRef]
25. Zhou Y, Gao X, Yuan M, Yang B, He Q, Cao J. Targeting Myc interacting proteins as a winding path in cancer therapy. Front Pharmacol. 2021;12:748852. [CrossRef]
26. Zhang H, Zhai X, Liu Y, et al. NOP2-mediated m5C modification of c-Myc in an EIF3A-dependent manner to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Research (Wash D C). 2023;6:0184. [CrossRef]
27. Zhao H, Song L. TKP, a serine protease from Trichosanthes kirilowii, inhibits cell proliferation by blocking aerobic glycolysis in hepatocellular carcinoma cells. Nutr Cancer. 2022;74(1):333-345. [CrossRef]
28. Wang H, Ju D, Kho DH, et al. The ubiquitin specific protease USP34 protects the ubiquitin ligase gp78 from proteasomal degradation. Biochem Biophys Res Commun. 2019;509(2):348-353. [CrossRef]
29. Pan Y, Yuan F, Lin Z, Li Y. BPTF promotes glioma development through USP34-mediated de-ubiquitination of FOXC1. Histol Histopathol. 2025;40(2):205-214. [CrossRef]